DOCSLIB.ORG

Atrophy of Foot Muscles a Measure of Diabetic Neuropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atrophy of Foot Muscles a Measure of Diabetic Neuropathy Pathophysiology/Complications ORIGINAL ARTICLE Atrophy of Foot Muscles A measure of diabetic neuropathy 1 HENNING ANDERSEN, MD, PHD athy that is easily detected in the feet and 1 MICHAELA D. GJERSTAD, MD is closely related to the severity of neurop- 1 JOHANNES JAKOBSEN, MD, PHD athy. In the present study, foot muscle volume was studied in a group of long- term diabetic patients with and without neuropathy and in a group of nondiabetic control subjects. OBJECTIVE — Diabetic neuropathy is a length-dependent process that leads to reduced muscle strength and atrophy of leg muscles in some patients. We hypothesized that intrinsic foot muscles are atrophied in diabetic neuropathy and that the degree of atrophy is a measure of RESEARCH DESIGN AND motor dysfunction closely related to the neuropathic process. METHODS — Twenty-three type 1 RESEARCH DESIGN AND METHODS — Consecutive cross-sectional magnetic reso- diabetic patients (16 men and 7 women) nance images of the nondominant foot were obtained for stereological determination of the total aged 46 years (median, range 27–62) volume of the intrinsic foot muscles (VFM) in 23 long-term diabetic patients with (n ϭ 15) and with a median diabetes duration of 29 without (n ϭ 8) chronic neuropathy and in 23 matched healthy nondiabetic control subjects. years (range 16–38) were included. The Based on clinical examination, nerve conduction studies, and quantitative sensory examination, mean body weight and body height were a neuropathy rank-sum score was calculated for each patient. 73 kg (range 53–92) and 176 cm (range 155–186), respectively. Diabetic patients 3 RESULTS — Total VFM was 86 Ϯ 52, 165 Ϯ 34, and 168 Ϯ 42 cm in neuropathic patients, without and with various degrees of neu- Ͻ nonneuropathic patients, and healthy control subjects, respectively (P 0.001). There was a ropathy were selected without paying at- close inverse relationship between the neuropathy rank-sum score and the VFM (r ϭϪ0.75, P Ͻ Ϫ tention to symptoms and signs of motor 1 ϫ 10 5). disturbances. Patients with severe cardiac CONCLUSIONS — Total volume of the foot muscles is halved in patients with diabetic or lung disease, acute or chronic muscu- neuropathy. Atrophy of foot muscles is closely related to the severity of neuropathy and reflects loskeletal disorders, acute metabolic dys- motor dysfunction. regulation, other neurological or endocrine disorders, or any previous or Diabetes Care 27:2392–2385, 2004 present lower-limb asymmetric proximal weakness were excluded. None of the pa- tients had a history of foot ulcer or symp- oss of ankle jerks and of sensation in related to muscle atrophy, whereas non- toms or signs of arterial insufficiency in the feet are early clinical signs of neuropathic patients have normal muscle the lower extremities. All case records L chronic polyneuropathy in diabetes. strength and striated muscle mass (3). In were searched for other explanations of In contrast, motor weakness with loss of the more distally situated intrinsic foot polyneuropathy, and all patients were ex- the ability to stand on the heels occurs late muscles, Brash et al. (4) observed atrophy amined by a trained neurologist who de- in the clinical course and only in a minor- in neuropathic diabetic patients using a cided whether the findings were typical of ity of diabetic patients. Previous studies specific magnetic resonance imaging diabetic neuropathy. None of the patients on motor function in diabetic neuropathy (MRI) contrast sequence; however, the at- had any significant toe or foot deformity. have relied on simple clinical tests such as rophy was not quantified. Since diabetic Twenty-three healthy control subjects the ability to stand on heels (1) and neu- polyneuropathy shows a centripetal pat- were included and matched for sex. They rophysiological examinations of motor tern of progression, quantification of the had a median age of 46 years (range 27– nerves (2). In a series of experiments in more distally situated foot muscles could 61), body height of 179 cm (range 160– long-term diabetic patients, we have ob- possibly serve as an early marker for mo- 185), and body weight of 69 kg (range served that muscle weakness in the lower- tor dysfunction in diabetic neuropathy. 55–97). All patients and control subjects leg muscles occurs to a substantial degree We hypothesized that muscular atro- gave informed consent to the study, in chronic neuropathic patients, closely phy is an integral part of diabetic neurop- which was approved by the local ethics ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● committee. The nondominant foot of all patients From the 1Department of Neurology, Aarhus University Hospital, Aarhus, Denmark; and the 2Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus, Denmark. and control subjects was visualized by Address correspondence and reprint requests to Henning Andersen, Department of Neurology, Aarhus MRI using a 1.0 Tesla scanner (Sigma University Hospital, 8000 Aarhus C, Denmark. E-mail: [email protected]. GE). All MRI scans were obtained with a Received for publication 14 April 2004 and accepted in revised form 15 July 2004. conventional T1-weighted Spin-Echo se- Abbreviations: MRI, magnetic resonance imaging; VFM, volume of the intrinsic foot muscles. A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion quence (echo time 20 ms, repetition time factors for many substances. 540 ms) using 4-mm cross-sectional mag- © 2004 by the American Diabetes Association. netic resonance images and an intersec- 2382 DIABETES CARE, VOLUME 27, NUMBER 10, OCTOBER 2004 Andersen, Gjerstad, and Jakobsen Figure 1—Total volume of all foot muscles in 15 type 1 diabetic patients with neuropathy, in 8 nonneuropathic type 1 diabetic patients, and in 23 nondiabetic healthy control subjects (A). Values are means Ϯ SD. Below is a cross-sectional magnetic resonance image at the metatarsal level of the foot in a neuropathic patient (B), in a nonneuropathic patient (C), and in a nondiabetic control subject (D) showing that the neuropathic diabetic patient has a substantial reduction of muscle tissues. *P Ͻ 0.001, neuropathic patients compared with nonneuropathic patients and nondiabetic control subjects. tion interval of 10 mm. A 256 ϫ 256 by a single observer using a stereological mined for the dominant median and matrix and two excitations were used. point-counting method as described pre- nondominant peroneal nerve using an The magnetic resonance images were viously (3,5). The total volume of striated electromyograph (Dantec Counterpoint) converted to digital pictures for analysis muscle (in cubic centimeters) was calcu- and standard methods. Vibratory percep- on a PC (Chameleon; Olympus). The lated by multiplying the distance between tion thresholds were evaluated at the identity of the magnetic resonance images the sections by the total cross-sectional dominant index finger pulp and at the was blinded to the observers. Within the area, the first section being randomly nondominant dorsum of the great toe us- muscle compartments, an upper level of placed within the first interslice 10-mm ing forced-choice techniques (Case IV; signal intensity for muscle tissues was de- interval. For further analysis, the volume WR Medical Electronics). A neuropathy fined. Signal intensities above this level for each patient was expressed as a per- rank-sum score was calculated for each were comparable with signal intensities of centage of the value of the individually patient based on the findings of the neu- fat tissues, allowing a separation of mus- matched control subject. ropathy symptom score, neurological im- cle tissues from “nonmuscle tissues” All patients were evaluated clinically pairment score, vibratory perception within the muscle compartments. Muscle according to a neuropathy symptom threshold test, and motor nerve conduc- fascia, tendons, and blood vessels were score (6) and a neurological impairment tion velocity, a high score reflecting severe excluded. At each image, the cross- score (7). Motor nerve conduction veloc- nerve dysfunction. The minimal criteria sectional area of all muscles was estimated ity and response amplitudes were deter- for diabetic neuropathy were adopted and DIABETES CARE, VOLUME 27, NUMBER 10, OCTOBER 2004 2383 Atrophy of foot muscles in diabetic neuropathy lationship between degree of atrophy and degree of neuropathy based on clinical, electrophysiological, and quantitative sensory examinations. Loss of sensation, toe abnormalities, and foot ulcers are easily recognized at the clinical examination of a diabetic foot. In contrast, evaluation of the motor system is hampered by the inability to evaluate the strength of foot muscles and difficulties estimating muscle mass. In a previous study of diabetic patients, we have found a very close relationship between the vol- ume of muscles and strength of ankle dor- sal and plantar flexors (r values Ͼ0.8) (3). This clearly indicates that determination of muscle mass reflects motor function. In healthy subjects, r values between muscle strength and total muscle volume ex- Figure 2—The relationship between the neuropathy rank-sum score and the volume of foot ceeded 0.85, a slightly closer relation than muscles in all diabetic patients given as a percentage of their individually matched control values the one between muscle cross-sectional (r ϭϪ0.75, P Ͻ 0.0001). area and muscle strength (4). Volume of striated muscles in the foot was determined using a stereological applied for separation of neuropathic and with neuropathy is one-half that of con- point-counting method (8). This method nonneuropathic patients (1). trol subjects and also one-half that of di- provides an unbiased estimation of the Statistical comparisons between abetic patients without neuropathy. volume of any structure of interest within groups were made with ANOVA, and cor- Expressed relative to their individually an object pending unequivocal definition relations were sought for using linear re- matched control subjects, the median of the structure, irrespective of the form of gression analysis.
Load more

Recommended publications
  • Efficacy of Texture and Color Enhancement Imaging In
    www.nature.com/scientificreports OPEN Efcacy of Texture and Color Enhancement Imaging in visualizing gastric mucosal atrophy and gastric neoplasms Tsubasa Ishikawa1, Tomoaki Matsumura1*, Kenichiro Okimoto1, Ariki Nagashima1, Wataru Shiratori1, Tatsuya Kaneko1, Hirotaka Oura1, Mamoru Tokunaga1, Naoki Akizue1, Yuki Ohta1, Keiko Saito1, Makoto Arai1,2, Jun Kato1 & Naoya Kato1 In 2020, Olympus Medical Systems Corporation introduced the Texture and Color Enhancement Imaging (TXI) as a new image-enhanced endoscopy. This study aimed to evaluate the visibility of neoplasms and mucosal atrophy in the upper gastrointestinal tract through TXI. We evaluated 72 and 60 images of 12 gastric neoplasms and 20 gastric atrophic/nonatrophic mucosa, respectively. The visibility of gastric mucosal atrophy and gastric neoplasm was assessed by six endoscopists using a previously reported visibility scale (1 = poor to 4 = excellent). Color diferences between gastric mucosal atrophy and nonatrophic mucosa and between gastric neoplasm and adjacent areas were assessed using the International Commission on Illumination L*a*b* color space system. The visibility of mucosal atrophy and gastric neoplasm was signifcantly improved in TXI mode 1 compared with that in white-light imaging (WLI) (visibility score: 3.8 ± 0.5 vs. 2.8 ± 0.9, p < 0.01 for mucosal atrophy; visibility score: 2.8 ± 1.0 vs. 2.0 ± 0.9, p < 0.01 for gastric neoplasm). Regarding gastric atrophic and nonatrophic mucosae, TXI mode 1 had a signifcantly greater color diference than WLI (color diferences: 14.2 ± 8.0 vs. 8.7 ± 4.2, respectively, p < 0.01). TXI may be a useful observation modality in the endoscopic screening of the upper gastrointestinal tract.
    [Show full text]
  • Gas Gangrene Infection of the Eyes and Orbits
    Br J Ophthalmol: first published as 10.1136/bjo.69.2.143 on 1 February 1985. Downloaded from British Journal of Ophthalmology, 1985, 69, 143-148 Gas gangrene infection of the eyes and orbits GERARD W CROCK,' WILSON J HERIOT,' PATTABIRAMAN JANAKIRAMAN,' AND JOHN M WEINER2 From the 'Department of Ophthalmology, University ofMelbourne, and the2C H Greer Pathology Laboratory, the Royal Victorian Eye and Ear Hospital, East Melbourne, Australia SUMMARY The literature on Clostridium perfringens infections is reviewed up to 1983. An additional case is reported with bilateral clostridial infections of the eye and orbit. One eye followed the classical course of relentless panophthalmitis, amaurosis, and orbital cellulitis ending in enucleation. The second eye contained intracameral mud and gas bubbles that were removed by vitrectomy instrumentation. Subsequent removal of the toxic cataract resulted in a final aided visual acuity of 6/18, N8. This is the third report of a retained globe, and we believe the only known case where the patient was left with useful vision. Clostridium perfringens is a ubiquitous Gram- arms, chest, and abdomen. He was admitted to a positive bacillus found in soil and bowel flora. It is the general hospital, where he was examined under most common of four clostridia species identified in anaesthesia, and his injuries were attended to. copyright. cases of gas gangrene in man.' All species are obligate Ocular findings. The right cornea and anterior anaerobes and are usually saprophytic rather than chamber were intact. There was a scleral laceration pathogenic. Clostridium perfringens is a feared con- over the superonasal area of the pars plana with taminant of limb injuries and may result in death due vitreous prolapse.
    [Show full text]
  • Gluteal Muscle Contracture: Diagnosis and Management Options
    SICOT J 2017, 3,1 Ó The Authors, published by EDP Sciences, 2017 DOI: 10.1051/sicotj/2016036 Available online at: www.sicot-j.org REVIEW ARTICLE OPEN ACCESS Gluteal muscle contracture: diagnosis and management options Saroj Rai1, Chunqing Meng1,*, Xiaohong Wang1, Nabin Chaudhary2, Shengyang Jin1, Shuhua Yang1, and Hong Wang1 1 Department of Orthopedics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, #1277 Jiefang Avenue, 430022 Wuhan, P.R. China 2 Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, #1095 Jiefang Avenue, 430030 Wuhan, P.R. China Received 14 April 2016, Accepted 29 October 2016, Published online 6 January 2017 Abstract – Gluteal muscle contracture (GMC), a debilitating disease, exists all over the globe but it is much more prevalent in China. Patients typically present with abduction and external rotation of the hip and are unable to bring both the knees together while squatting. Multiple etiologies have been postulated, the commonest being repeated intramuscular injection into the buttocks. The disease is diagnosed primarily by clinical features but radiological features are necessary for the exclusion of other pathological conditions. Non-operative treatment with physiotherapy can be tried before surgery is considered but it usually fails. Different surgical techniques have been described and claimed to have a better outcome of one over another but controversy still exists. Based on published literatures, the clinical outcome is exceptionally good in all established methods of surgery. However, endoscopic surgery is superior to conventional open surgery in terms of cosmetic outcome with fewer complications. Nevertheless, its use has been limited by lack of adequate knowledge, instrumentations, and some inherent limitations.
    [Show full text]
  • Cancer Cachexia Decreases Specific Force and Accelerates Fatigue in Limb Muscle
    Biochemical and Biophysical Research Communications 435 (2013) 488–492 Contents lists available at SciVerse ScienceDirect Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc Cancer cachexia decreases specific force and accelerates fatigue in limb muscle ⇑ B.M. Roberts a, G.S. Frye b, B. Ahn b, L.F. Ferreira b,1, A.R. Judge a,1, a 1225 Center Drive, HPNP Building Room 1142, Department of Physical Therapy, University of Florida, Gainesville, FL 32610, USA b 1864 Stadium Road, Department of Applied Physiology & Kinesiology, University of Florida, Gainesville, FL 32610, USA article info abstract Article history: Cancer cachexia is a complex metabolic syndrome that is characterized by the loss of skeletal muscle Received 30 April 2013 mass and weakness, which compromises physical function, reduces quality of life, and ultimately can Available online 11 May 2013 lead to mortality. Experimental models of cancer cachexia have recapitulated this skeletal muscle atro- phy and consequent decline in muscle force generating capacity. However, more recently, we provided Keywords: evidence that during severe cancer cachexia muscle weakness in the diaphragm muscle cannot be Muscle weakness entirely accounted for by the muscle atrophy. This indicates that muscle weakness is not just a conse- Muscle atrophy quence of muscle atrophy but that there is also significant contractile dysfunction. The current study C-26 aimed to determine whether contractile dysfunction is also present in limb muscles during severe Contractile dysfunction Colon-26 (C26) carcinoma cachexia by studying the glycolytic extensor digitorum longus (EDL) muscle and the oxidative soleus muscle, which has an activity pattern that more closely resembles the dia- phragm.
    [Show full text]
  • Spinal Muscular Atrophy Testing
    Lab Management Guidelines v2.0.2019 Spinal Muscular Atrophy Testing MOL.TS.225.B v2.0.2019 Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline SMN1 Gene Analysis; Dosage/Deletion 81329 Analysis (eg, carrier testing), includes SMN2 Analysis, if performed SMN1 Full Gene Sequencing 81336 SMN1 Known Familial Mutation Analysis 81337 What is spinal muscular atrophy Definition Spinal muscular atrophy (SMA) is a severe, autosomal recessive neuromuscular disease that affects 1 in 8000 to 1 in 10,000 people.1,2 SMA is caused by loss of lower motor neurons (anterior horn cells) in the spinal cord, resulting in progressive symmetrical muscle weakness and atrophy.1-3 SMA has historically been divided into three to five clinical subtypes based on age of onset and clinical course. While genetic testing has shown these clinical subtypes are not completely distinct, they are still widely used, and include:1-3 o Prenatal onset form (“Type 0” proposed) is characterized by polyhydramnios, decreased fetal movements, breech presentation, arthrogryposis multiplex congenita, respiratory failure at birth, and life span less than 6 months. o Type I (infantile or Werdnig-Hoffmann type) is the most common form (60-70% of cases). It presents before 6 months of age with death often before age 2 due to respiratory failure. Affected children have severe, generalized weakness and do not ever sit without support.
    [Show full text]
  • Short Course 10 Metaplasia in The
    0 3: 436-446 Rev Esp Patot 1999; Vol. 32, N © Prous Science, SA. © Sociedad Espajiola de Anatomia Patot6gica Short Course 10 © Sociedad Espafiola de Citologia Metaplasia in the gut Chairperson: NA. Wright, UK. Co-chairpersons: G. Coggi, Italy and C. Cuvelier, Belgium. Overview of gastrointestinal metaplasias only in esophagus but also in the duodenum, intestine, gallbladder and even in the pancreas. Well established is columnar metaplasia J. Stachura of esophageal squamous epithelium. Its association with increased risk of esophageal cancer is widely recognized. Recent develop- Dept. of Pathomorphology, Jagiellonian University ments have suggested, however, that only the intestinal type of Faculty of Medicine, Krakdw, Poland. metaplastic epithelium (classic Barrett’s esophagus) predisposes to cancer. Another field of studies is metaplasia in the short seg- ment at the esophago-cardiac junction, its association with Metaplasia is a reversible change in which one aduit cell type is Helicobacter pylon infection and/or reflux disease and intestinal replaced by another. It is always associated with some abnormal metaplasia in the cardiac and fundic areas. stimulation of tissue growth, tissue regeneration or excessive hor- Studies on gastric mucosa metaplasia could be divided into monal stimulation. Heterotopia, on the other hand, takes place dur- those concerned with pathogenesis and detailed structural/func- ing embryogenesis and is usually supposed not to be associated tional features and those concerned with clinical significance. with tissue damage. Pancreatic acinar cell clusters in pediatric gas- We know now that gastric mucosa may show not only complete tric mucosa form another example of aberrant cell differentiation. and incomplete intestinal metaplasia but also others such as ciliary Metaplasia is usually divided into epithelial and connective tis- and pancreatic metaplasia.
    [Show full text]
  • Hyperplasia (Growth Factors
    Adaptations Robbins Basic Pathology Robbins Basic Pathology Robbins Basic Pathology Coagulation Robbins Basic Pathology Robbins Basic Pathology Homeostasis • Maintenance of a steady state Adaptations • Reversible functional and structural responses to physiologic stress and some pathogenic stimuli • New altered “steady state” is achieved Adaptive responses • Hypertrophy • Altered demand (muscle . hyper = above, more activity) . trophe = nourishment, food • Altered stimulation • Hyperplasia (growth factors, . plastein = (v.) to form, to shape; hormones) (n.) growth, development • Altered nutrition • Dysplasia (including gas exchange) . dys = bad or disordered • Metaplasia . meta = change or beyond • Hypoplasia . hypo = below, less • Atrophy, Aplasia, Agenesis . a = without . nourishment, form, begining Robbins Basic Pathology Cell death, the end result of progressive cell injury, is one of the most crucial events in the evolution of disease in any tissue or organ. It results from diverse causes, including ischemia (reduced blood flow), infection, and toxins. Cell death is also a normal and essential process in embryogenesis, the development of organs, and the maintenance of homeostasis. Two principal pathways of cell death, necrosis and apoptosis. Nutrient deprivation triggers an adaptive cellular response called autophagy that may also culminate in cell death. Adaptations • Hypertrophy • Hyperplasia • Atrophy • Metaplasia HYPERTROPHY Hypertrophy refers to an increase in the size of cells, resulting in an increase in the size of the organ No new cells, just larger cells. The increased size of the cells is due to the synthesis of more structural components of the cells usually proteins. Cells capable of division may respond to stress by undergoing both hyperrtophy and hyperplasia Non-dividing cell increased tissue mass is due to hypertrophy.
    [Show full text]
  • Ghasemi Gh. Comparison of Laparoscopic Ovarian Drilling
    Archive of SID Original Article Comparison of Laparoscopic Ovarian Drilling Success between Two Standard and Dose-Adjusted Methods in Polycystic Ovary Syndrome: A Randomized Clinical Trial Leili Hafizi, M.D.1, Maliheh Amirian, M.D.2, Yasmin Davoudi, M.D.3, Mona Jaafari, M.D.1, Ghazal Ghasemi, M.D.1* 1. Department of Obstetrics and Gynaecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2. Department of IVF and Infertility, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 3. Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Abstract Background: One of the treatment methods for increasing the ovarian response to ovulation induction in polycystic ovary syndrome (PCOS) is laparoscopic ovarian drilling (LOD). The optimal amount of the electrosurgical energy discharged in the ovaries to achieve maximum treatment response with minimal follicle injury is unknown. This study was performed to compare the success level of LOD by means of standard and dose-adjusted treatment methods among infertile clomiphene-resistant PCOS women. Materials and Methods: This randomized clinical trial was conducted on infertile clomiphene citrate-resistant PCOS women in the Gynaecology Department of Imam Reza Hospital between 2016 and 2017. The patients were randomly di- vided into two groups based on the ovarian cautery method. The two groups were examined and compared regarding the antral follicles, the serum levels of anti-Müllerian hormone (AMH), androgens, and mid-luteal progesterone one month after surgery. The regularity of cycles, ovulation, and pregnancy were examined monthly up to six months after surgery. Results: In total, 60 women received bilateral LOD (n=30 per group).
    [Show full text]
  • Cellular Adaptation
    Cellular Adaptation Dr. Adeboye OO (MBBS, Cert. LMIH, FMCPath) Dept of Anatomic Pathology Bowen University Cellular adaptation • Cell death is not the only consequence of cellular injury or stress • Cells can respond to excessive physiologic or pathologic stimuli by undergoing both functional and morphologic change in which a new steady state is achieved that preserves the viability of the cell(Adaptation) . • The adaptive response include- • Adaptation of growth and differentiation • Intracellular accumulation • Pathologic calcification • Hyaline change • Cellular aging Adaptation of growth and differentiation • Adaptations are reversible changes in the size, number,phenotype, metabolic activity, or functions of cells in response to changes in their environment. Such adaptations may take several distinct forms : • 1. hyperplasia • 2. hypertrophy • 3. atrophy • 4. metaplasia hypertrophy • Increase in the size of cells that result in the increase in size of the affected organ. • No new cells just larger cells • May coexist with hyperplasia in cells capable of division( eg epithelial, hematopoesis etc), in non dividing cells (eg the nerve ,cardiac and skeletal muscle) increase tissue mass is due to hypertrophy • Can be physiologic or pathologic Physiologic hypertrophy • Caused by- (a) increased functional demand eg hypertrophy of striated muscle in muscle builder.(b) stimulation by hormones or growth factors eg physiologic hypertrophy of the uterus during pregnancy Hypertrophy of uterus during pregnancy Micrograph showing smooth muscle
    [Show full text]
  • Brain-Derived Circulating Cell-Free DNA Defines the Brain Region and Cell Specific Origins Associated with Neuronal Atrophy
    bioRxiv preprint doi: https://doi.org/10.1101/538827; this version posted February 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Brain-derived circulating cell-free DNA defines the brain region and cell specific origins associated with neuronal atrophy Chatterton. Zac1,2,4,6,9*, Mendelev. Natalia1,2,4,6, Chen. Sean1,2,4,6, Raj. Towfique1,2, Walker. Ruth1,2,6,7, Carr. Walter10,11, Kamimori. Gary10, Beeri. Michal8, Ge. Yongchao4, Dwork. Andrew5, Haghighi. Fatemeh1,2,4,6* *Corresponding author. Email: [email protected] & [email protected] 1Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 2Department of Neuroscience, 3Department of Psychiatry, 4Department of Neurology, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029. 5Department of Pathology and Cell Biology, Columbia University, New York, USA. 6Medical Epigenetics, James J. Peters VA Medical Center, Bronx, USA. 7Department of Neurology, James J. Peters VA Medical Center, Bronx, USA 8The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel 9Brain and Mind Centre, The University of Sydney, Camperdown, Australia 10Walter Reed Army Institute of Research, Silver Spring, MD, USA 11Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA Liquid biopsies are revolutionizing the fields non-invasive prenatal testing (NIPT). The of prenatal non-invasive testing and cancer technological advancements in NGS have diagnosis by leveraging the genetic differences increased the limits of detection of these between mother and fetus, and, host and techniques [4] to ~0.02%, which hold the cancer.
    [Show full text]
  • Spinal Muscular Atrophy
    FACT SHEET SPINAL MUSCULAR ATROPHY Spinal Muscular Atrophy (SMA) is a Motor Neuron Disease. It is caused by the mutation of the Survival of SYMPTOMS IN INFANTS • Muscle weakness. Motor Neuron (SMN) gene. It occurs due to the loss of • Muscle atrophy (wasting). motor neurons within the spinal cord and brain. It results • Poor muscle tone. in the progressive wasting away of muscles (atrophy) and • Areflexia (delayed reflexes). muscle weakness. SMA can affect people of all ages, races • Weak cry. or genders; however, the majority of cases occur in infancy • Difficulty sucking or swallowing. or childhood. There are four types of SMA. • Feeding difficulties. FORMS OF SMA • Weak cough. • Lack of developmental milestones (inability to lift head TYPE I (ACUTE INFANTILE) or sit up). • Also called Wernig-Hoffman Disease. • Limpness or a tendency to flop. • Most severe form of SMA. • Accumulations of secretions in the lungs or throat. • Usually diagnosed before six months of age. • Those affected cannot sit without support, lungs may SYMPTOMS IN ADULTS not fully develop, swallowing and breathing may be • Muscle weakness. difficult and there is weakness of the intercostal muscles • Muscle atrophy (wasting). (muscles between the ribs). • Weak tongue. • 95 per cent fatal by 18 • Stiffness. • Cramps. TYPE II (CHRONIC INFANTILE) • Fasciculation (twitching). • Usually diagnosed before the age of two, with the • Clumsiness. majority of cases diagnosed by 15 months. • Dyspnea (shortness of breath). • May be able to sit without assistance or even stand with support. DIAGNOSIS • Increased risk for complications from respiratory • A diagnosis can be made by an SMN gene test which infections.
    [Show full text]
  • Skeletal Muscle Damage in COVID-19: a Call for Action
    medicina Review Skeletal Muscle Damage in COVID-19: A Call for Action Amira Mohammed Ali 1,2,* and Hiroshi Kunugi 3,4 1 Department of Psychiatric Nursing and Mental Health, Faculty of Nursing, Alexandria University, Alexandria 21527, Egypt 2 Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo 187-8553, Japan 3 Department of Psychiatry, School of Medicine, Teikyo University, Tokyo 173-8605, Japan; [email protected] 4 Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan * Correspondence: [email protected]; Tel.: +81-042-346-1986 Abstract: Both laboratory investigations and body composition quantification measures (e.g., com- puted tomography, CT) portray muscle loss in symptomatic Coronavirus disease 2019 (COVID-19) patients. Muscle loss is associated with a poor prognosis of the disease. The exact mechanism of muscle damage in COVID-19 patients, as well as the long-term consequences of muscle injury in disease survivors, are unclear. The current review briefly summarizes the literature for mechanisms, assessment measures, and interventions relevant to skeletal muscle insult in COVID-19 patients. Muscle injury is likely to be attributed to the cytokine storm, disease severity, malnutrition, prolonged physical inactivity during intensive care unit (ICU) stays, mechanical ventilation, and myotoxic drugs (e.g., dexamethasone). It has been assessed by imaging and non-imaging techniques (e.g., CT and electromyography), physical performance tests (e.g., six-minute walk test), anthropometric measures (e.g., calf circumference), and biomarkers of muscle dystrophy (e.g., creatine kinase). Interventions Citation: Ali, A.M.; Kunugi, H.
    [Show full text]